DigiPath Appoints Imaging & Laboratory Veteran as CEO
, June 3, 2014
/PRNewswire/ -- DigiPath, Inc. (OTCBB and OTCQB: DIGP), a life sciences company focused on nutra-pharmaceuticals and pathology solutions, is pleased to announce the appointment of laboratory and imaging industry veteran Steven D. Barbee
as Chief Executive Officer.
"Mr. Barbee's leadership in the laboratory and imaging technology industries is unparalleled," said Todd Denkin, President of DigiPath Inc. "As President of DigiPath since April 2014, and Vice President of DigiPath since February 2012, his style and ethics make him the perfect choice to fill the position of CEO of DigiPath Inc. as the company expands into botanical and nutraceutical marketplaces."
"DigiPath stands at a unique and exciting point in its corporate history," said Mr. Barbee. "After building an extensive digital imaging franchise, I'm excited to take the helm as we expand into the nutra-pharmaceutical industry with the research, development, licensing, and operation of botanical and nutra-pharmaceutical products and services."
Before coming to DigiPath, Barbee was Vice President of Sales, International and Government Affairs at BioImagene, Inc., a laboratory imaging company that was acquired by Roche Corporation in the fall of 2010. Prior to joining BioImagene, Barbee was the vice president of sales and marketing at Trestle Corporation, another laboratory imaging company. Trestle was acquired by Clarient, Inc. in the fall of 2006. His career until joining Trestle includes key sales and sales leadership positions in telecom companies, including Zyan Communications, Inc., Level 3 Communications, Inc., ICG Telecom Group, and AT&T.
About DigiPath, Inc.
DigiPath, Inc., through its subsidiary, DigiPath, Corp., creates and markets innovative and reliable digital pathology solutions that empower private and academic institutions with the ability to create, store, manage, analyze, and correlate data collected through virtual microscopy. DigiPath, Inc. digital pathology portfolio includes PathScope, PathCloud, PathReview, and PathConsult digital platforms to share and store archive tissue images. DigiPath, Inc. is expanding into new lines of business associated with the research, development, licensing and operation of botanical and nutrapharmaceutical products and services.
For more information about this announcement or the company, please visit: www.digipath.com.
Information about Forward-Looking Statements
This press release contains "forward-looking statements" that include information relating to future events and future financial and operating performance. The words "may," "would," "will," "expect," "estimate," "can," "believe," "potential" and similar expressions and variations thereof are intended to identify forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by, which that performance or those results will be achieved. Forward-looking statements are based on information available at the time they are made and/or management's good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Important factors that could cause these differences include, but are not limited to: fluctuations in demand for the Company's products, the introduction of new products, the Company's ability to maintain customer and strategic business relationships, the impact of competitive products and pricing, growth in targeted markets, the adequacy of the Company's liquidity and financial strength to support its growth, and other information that may be detailed from time-to-time in the Company's filings with the United States Securities and Exchange Commission. An example of such forward looking statements in this press release include statements regarding the Company developing and completing new products. For a more detailed description of the risk factors and uncertainties affecting DigiPath, please refer to the Company's recent Securities and Exchange Commission filings, which are available at www.sec.gov. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
David Williams, CFO
SOURCE DigiPath, Inc.